Jenburkt Pharmaceuticals Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, the company's net sales/income from operations was INR 176.3 million compared with INR 143.9 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 18.7 million compared with INR 15.4 million a year ago. Profit from ordinary activities before tax was INR 21.6 million compared with INR 17.2 million a year ago. Net profit was INR 14.4 million or INR 3.10 per basic and diluted share compared with INR 11.4 million or INR 2.46 per basic and diluted share a year ago.

For the nine months, the company's net sales/income from operations was INR 520.8 million compared with INR 440.6 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 64.9 million compared with INR 61.2 million a year ago. Profit from ordinary activities before tax was INR 64.6 million compared with INR 60.1 million a year ago. Net profit was INR 45.4 million or INR 9.77 per basic and diluted share compared with INR 42.6 million or INR 9.17 per basic and diluted share a year ago.